Basking Biosciences Completes $5.4M Seed Financing: Funds to Support Development of the 1st Reversible Thrombolytic Therapy for Acute Ischemic Stroke
The investor syndicate includes Rev1 Ventures, Broadview Ventures, and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview, and Dr. Dan Meyers have joined Basking’s Board of Directors.